Results 151 to 160 of about 319,385 (305)

Swallowing the interdisciplinary pill [PDF]

open access: yes, 2010
Klaf, Suzanna   +2 more
core   +1 more source

Stillbirth in pregnancies with flat OGTT: Placental clues to occult maternal dysmetabolism

open access: yes
International Journal of Gynecology &Obstetrics, EarlyView.
Emma Bertucci   +10 more
wiley   +1 more source

Does timing of systemic antibiotics influence periodontal treatment outcomes? A randomized clinical trial

open access: yesJournal of Periodontology, EarlyView.
Abstract Background The aim of this study is to determine whether the timing of metronidazole (MTZ) and amoxicillin (AMX) administration, relative to scaling and root planing (SRP), influences the clinical and microbiological outcomes of periodontal treatment.
Daiane Fermiano   +10 more
wiley   +1 more source

Indirect effects of Seeking Safety plus sertraline on alcohol use: The mediating role of reductions in posttraumatic stress disorder symptom severity

open access: yesJournal of Traumatic Stress, EarlyView.
Abstract Posttraumatic stress disorder (PTSD) symptoms and alcohol use frequently co‐occur and are mutually reinforcing. Few studies have examined how changes in PTSD severity influence subsequent changes in alcohol use, particularly in the context of comorbidity treatments. This secondary analysis utilized data from a clinical trial comparing 12 weeks
Lesia M. Ruglass   +11 more
wiley   +1 more source

Misinformation and women's health: Rebuilding trust in evidence‐based care

open access: yes
International Journal of Gynecology &Obstetrics, EarlyView.
Zainab Al‐Jawahiri
wiley   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy